Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Brief Summary: This is an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study will allow dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose will be based on the subject's dose at the end of the TRA115450 study. The maximum dose will be 75 mg daily.